Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients

被引:58
作者
Alkan, Ali [1 ]
Yasar, Arzu [1 ]
Karci, Ebru [1 ]
Koksoy, Elif Berna [1 ]
Urun, Muslih [1 ]
Senler, Filiz Cay [1 ]
Urun, Yuksel [1 ]
Tuncay, Gulseren [2 ]
Ergun, Hakan [3 ]
Akbulut, Hakan [1 ]
机构
[1] Ankara Univ, Sch Med, Med Oncol, Ankara, Turkey
[2] Ankara Univ, Sch Med, Internal Med, Ankara, Turkey
[3] Ankara Univ, Sch Med, Pharmacol, Ankara, Turkey
关键词
Severe drug interaction; Potentially inappropriate medication; Elderly; Beers Criteria; Geriatric oncology; Polypharmacy; OLDER-PEOPLE; POLYPHARMACY; PREVALENCE; ADULTS; CHEMOTHERAPY; TOXICITY; THERAPY; CARE;
D O I
10.1007/s00520-016-3409-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Due to more comorbidities, polypharmacy is common in elderly patients and drug interactions are inevitable. It is also challenging to treat an elderly patient with a diagnosis of cancer. Prevalence and clinical impacts of drug interactions and using potentially inappropriate medications (PIMs) have been studied in geriatric patients. However, these are not well defined in oncology practice. The purpose of this study is to define the prevalence of PIMs and severe drug interactions (SDIs) in elderly cancer patients and investigate the factors associated with them. Patients more than 65 years of age in both inpatient and outpatient clinics were evaluated. Patient, disease characteristics, and medications used were collected by self reports and medical records. Drug interactions were checked with LexicompA (R) and PIM was defined with 2012 update of Beers criteria. Severe drug interactions are defined with category D or X DIs. Logistic regression was used to compute odds ratios (ORs) and 95 % confidence intervals (CIs) for the association between SDIs, PIMs, and clinical parameters. Four hundered and forty-five elderly patients (286 outpatient, 159 inpatient), with a median age of 70 (65-89) were evaluated. SDIs were present in 156 (35.1 %) of patients, 81 (28.3 %), and 75 (47.2 %) for outpatient and inpatients, respectively (p < 0.001). PIMs were present in 117 (26.6 %) of the patients, 40 (14.2 %), and 77(48.4 %) for outpatient and inpatients, respectively (p < 0.001). In multivariate analysis; polypharmacy (>= 5 drugs), inpatient status and diagnosis of lung cancer were associated with severe DIs. Polypharmacy, inpatient status, and bad performance score (ECOG 3-4) were associated with PIMs. Nearly one third of the elderly cancer patients are exposed to severe drug interactions and PIMs. Clinicians dealing with elderly cancer patients should be more cautious when prescribing/ planning drugs to this group of patients. More strategies should be developed in this group of patients to minimize the medications prescribed and prevent severe DIs.
引用
收藏
页码:229 / 236
页数:8
相关论文
共 22 条
  • [1] Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice
    Dushenkov, Anna
    Kalabalik, Julie
    Carbone, Antonia
    Jungsuwadee, Paiboon
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (04) : 296 - 308
  • [2] American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults
    Fick, Donna
    Semla, Todd
    Beizer, Judith
    Dombrowski, Robert
    Brandt, Nicole
    DuBeau, Catherine E.
    Flanagan, Nina
    Hanlon, Joseph
    Hollmann, Peter
    Linnebur, Sunny
    Nau, David
    Rehm, Bob
    Sandhu, Satinderpal
    Steinman, Michael
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2012, 60 (04) : 616 - 631
  • [3] Inappropriate medication use among the elderly: a systematic review of administrative databases
    Guaraldo, Lusiele
    Cano, Fabiola G.
    Damasceno, Glauciene S.
    Rozenfeld, Suely
    [J]. BMC GERIATRICS, 2011, 11
  • [4] Drug-drug interactions among elderly patients hospitalized for drug toxicity
    Juurlink, DN
    Mamdani, M
    Kopp, A
    Laupacis, A
    Redelmeier, DA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (13): : 1652 - 1658
  • [5] Polypharmacy Status as an Indicator of Mortality in an Elderly Population
    Jyrkka, Johanna
    Enlund, Hannes
    Korhonen, Maarit J.
    Sulkava, Raimo
    Hartikainen, Sirpa
    [J]. DRUGS & AGING, 2009, 26 (12) : 1039 - 1048
  • [6] Polypharmacy in the terminal stage of cancer
    Kierner, Katharina A.
    Weixler, Dietmar
    Masel, Eva K.
    Gartner, Verena
    Watzke, Herbert H.
    [J]. SUPPORTIVE CARE IN CANCER, 2016, 24 (05) : 2067 - 2074
  • [7] Anticancer Drug Therapy in the Older Cancer Patient: Pharmacology and Polypharmacy
    Lichtman, Stuart M.
    Boparai, Manpreet K.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2008, 9 (2-3) : 191 - 203
  • [8] Polypharmacy and Potentially Inappropriate Medication Use in Older Adults with Cancer Undergoing Chemotherapy: Effect on Chemotherapy-Related Toxicity and Hospitalization During Treatment
    Maggiore, Ronald J.
    Dale, William
    Gross, Cary P.
    Feng, Tao
    Tew, William P.
    Mohile, Supriya G.
    Owusu, Cynthia
    Klepin, Heidi D.
    Lichtman, Stuart M.
    Gajra, Ajeet
    Ramani, Rupal
    Katheria, Vani
    Zavala, Laura
    Hurria, Arti
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2014, 62 (08) : 1505 - 1512
  • [9] Polypharmacy in Older Adults with Cancer
    Maggiore, Ronald J.
    Gross, Cary P.
    Hurria, Arti
    [J]. ONCOLOGIST, 2010, 15 (05) : 507 - 522
  • [10] Prevalence of Unplanned Hospitalizations Caused by Adverse Drug Reactions in Older Veterans
    Marcum, Zachary A.
    Amuan, Megan E.
    Hanlon, Joseph T.
    Aspinall, Sherrie L.
    Handler, Steven M.
    Ruby, Christine M.
    Pugh, Mary Jo V.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2012, 60 (01) : 34 - 41